Harnessing bioinformatics to discover new vaccines

Drug Discovery Today

Volumn 12, Issue 9-10, 2007, Pages 389-395

  Davies, Matthew N ^a   Flower, Darren R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; CHEMOKINE RECEPTOR ANTAGONIST; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EPITOPE; GENOMIC DNA; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MENB VACCINE; MONTANIDE ISA 51; MURAMYL DIPEPTIDE; OUTER MEMBRANE PROTEIN F; PHOSPHORYL LIPID A; PLASMID DNA; POLYGLACTIN; QS 21; RESIQUIMOD; TRIPLE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; B LYMPHOCYTE; BIOINFORMATICS; CANCER IMMUNIZATION; CANCER PREVENTION; CHLAMYDOPHILA PNEUMONIAE; CODON; COMPUTER AIDED DESIGN; COMPUTER MODEL; COMPUTER PROGRAM; DNA IMMUNIZATION; DRUG DESIGN; DRUG RESEARCH; EPITOPE MAPPING; GENOME ANALYSIS; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPOTENTIATION; IMMUNOTHERAPY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OPEN READING FRAME; PREDICTION; PROTEIN ANALYSIS; PSEUDOMONAS AERUGINOSA; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TECHNIQUE; VACCINATION; WORLD HEALTH ORGANIZATION;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; EPITOPE MAPPING; HUMANS; SOFTWARE DESIGN; VACCINATION; VACCINES;

EID: 34247388467     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.03.010     Document Type: Review

References (68)

1. De Groot A.S. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov. Today 11 (2006) 203-209
2. De Groot A.S., and Berzofsky J.A. From genome to vaccine - new immunoinformatics tools for vaccine design. Methods 34 (2004) 425-428
3. McMurry J., et al. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb.) 85 (2005) 95-105
4. Rammensee H., et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
5. Jardetzky T.S., et al. Crystallographic analysis of endogenous peptides associated with HLADR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 734-738
6. Donnes P., and Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 3 (2002) 25. http://www.biomedcentral.com 10.1186/1471-2105-3-25
7. Liu W., et al. Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models. BMC Bioinformatics 7 (2006) 182. http://www.biomedcentral.com 10.1186/1471-2105-7-182
8. Wan J., et al. SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics 7 (2006) 463. http://www.biomedcentral.com 10.1186/1471-2105-7-463
9. Noguchi H., et al. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. J. Biosci. Bioeng. 94 (2002) 264-270
10. Burden F.R., and Winkler D.A. Predictive Bayesian neural network models of MHC class II peptide binding. J. Mol. Graph. Model. 23 (2005) 481-489
11. Reche P.A., and Reinherz E.L. PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res. 33 (2005) W138-W142
12. Doytchinova I.A., et al. Towards the chemometric dissection of peptide-HLA-A*0201 binding affinity: comparison of local and global QSAR models. J. Comput. Aided Mol. Des. 19 (2005) 203-212
13. Davies M.N., et al. Statistical deconvolution of enthalpic energetic contributions to MHC-peptide binding affinity. BMC Struct. Biol. 6 (2006) 5. http://www.biomedcentral.com 10.1186/1472-6807-6-5
14. Davies M.N., et al. A novel predictive technique for the MHC class II peptide-binding interaction. Mol. Med. 9 (2003) 220-225
15. 2m domains be neglected?. J. Comput. Chem. 25 (2004) 1803-1813
16. Doytchinova I.A., and Flower D.R. Class I T-cell epitope prediction: Improvements using a combination of proteasome cleavage, TAP affinity, and MHC binding. Mol. Immunol. 43 (2006) 2037-2044
17. TAP: a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Res. 2 (2006) 3. http://www.immunome-research.com 10.1186/1745-7580-2-3
18. Blythe M.J., and Flower D.R. Benchmarking B-cell epitope prediction: underperformance of existing methods. Protein Sci. 14 (2004) 246-248
19. Haste Andersen P., et al. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci. 15 (2006) 2558-2567
20. Schreiber A., et al. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J. Comput. Chem. 26 (2005) 879-887
21. Kulkarni-Kale U., et al. CEP: a conformational epitope prediction server. Nucleic Acids Res. 33 (2005) W168-W171
22. Rombel I.T., et al. ORF-FINDER: a vector for high-throughput gene identification. Gene 282 (2002) 33-41
23. Delcher A.L., et al. Improved microbial gene identification with GLIMMER. Nucleic Acids Res. 27 (1999) 4636-4641
24. Ou H.Y., et al. GS-Finder: a program to find bacterial gene start sites with a self-training method. Int. J. Biochem. Cell Biol. 36 (2004) 535-544
25. Servant F., et al. ProDom: Automated clustering of homologous domains. Brief. Bioinform. 3 (2002) 246-251
26. Bateman A., et al. The Pfam protein families database. Nucleic Acids Res. 28 (2000) 263-266
27. Falquet L., et al. The PROSITE database. Nucleic Acids Res. 30 (2002) 235-238
28. Bulashevska A., and Eils R. Predicting protein subcellular locations using hierarchical ensemble of Bayesian classifiers based on Markov chains. BMC Bioinformatics 7 (2006) 298-310
29. Tettelin H., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 (2000) 1809-1815
30. Pizza M., et al. Whole genome sequencing to identify vaccine candidates against serogroup B meningococcus. Science 287 (2000) 1816-1820
31. Wizemann T.M., et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69 (2001) 1593-1598
32. Maione D., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 (2005) 148-150
33. Ross B.C., et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19 (2001) 4135-4142
34. Rey S., et al. PSORTdb: a protein subcellular localization database for bacteria. Nucleic Acids Res. 33 (2005) D164-D168
35. Montigiani S., et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70 (2002) 368-379
36. Crameri R., and Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr. Opin. Immunol. 18 (2006) 761-768
37. Stadler M.B., and Stadler B.M. Allergenicity prediction by protein sequence. FASEB J. 17 (2003) 1141-1143
38. Soeria-Atmadja D., et al. Statistical evaluation of local alignment features predicting allergenicity using supervised classification algorithms. Int. Arch. Allergy Immunol. 133 (2004) 101-112
39. Ivanciuc O., et al. SDAP: database and computational tools for allergenic proteins. Nucleic Acids Res. 31 (2003) 359-362
40. Soeria-Atmadja D., et al. Computational detection of allergenic proteins attains a new level of accuracy with in silico variable-length peptide extraction and machine learning. Nucleic Acids Res. 34 (2006) 3779-3793
41. Linhart B., and Valenta R. Molecular design of allergy vaccines. Curr. Opin. Immunol. 17 (2005) 646-655
42. Bousquet J., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102 (1998) 558-562
43. Motta S., et al. Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res. 1 (2005) 5. http://www.immunome-research.com 10.1186/1745-7580-1-5
44. Pappalardo F., et al. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics 21 (2005) 2891-2897
45. Lollini P.L., et al. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator. BMC Bioinformatics 7 (2006) 352. http://www.biomedcentral.com 10.1186/1471-2105-7-352
46. Babiuk L.A., et al. Nucleic acid vaccines: research tool or commercial reality. Vet. Immunol. Immunopathol. 76 (2000) 1-23
47. Babiuk L.A., et al. Induction of immune responses by DNA vaccines in large animals. Vaccine 21 (2003) 649-658
48. Uchijima M., et al. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T-cell responses against an intracellular bacterium. J. Immunol. 161 (1998) 5594-5599
49. Klinman D.M., et al. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158 (1997) 3635-3639
50. Booth J.S., et al. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet. Immunol. Immunopathol. 115 (2007) 24-34
51. Lee A.H., et al. Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol. Cells 7 (1997) 495-501
52. Xu Z.L., et al. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 272 (2001) 149-156
53. Henry I., and Sharp P.M. Predicting gene expression level from codon usage bias. Mol. Biol. Evol. 24 (2007) 10-12
54. Harish N., et al. DyNAVacS: an integrative tool for optimized DNA vaccine design. Nucleic Acids Res. 34 (2006) W264-W266
55. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm. Res. 19 (2002) 715-728
56. Stills Jr. H.F. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46 (2005) 280-293
57. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32 (1998) 155-172
58. Singh M., and Srivastava I. Advances in vaccine adjuvants for infectious diseases. Curr. HIV Res. 1 (2003) 309-320
59. Schellhammer I., and Rarey M. FlexX-Scan: fast, structure-based virtual screening. Proteins 57 (2004) 504-517
60. Charoenvit Y., et al. A small peptide (CEL-1000) derived from the β-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob. Agents Chemother. 48 (2004) 2455-2463
61. Godessart N. Chemokine receptors: attractive targets for drug discovery. Ann. N. Y. Acad. Sci. 1051 (2005) 647-657
62. Johnson Z., et al. Chemokine inhibition-why, when, where, which and how?. Biochem. Soc. Trans. 32 (2004) 366-377
63. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001) 1236-1237
64. Peters B., et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput. Biol. 2 (2006) e65. http://compbiol.plosjournals.org 10.1371/journal.pcbi.0020065
65. Doytchinova I.A., and Flower D.R. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 8 (2007) 4. http://www.biomedcentral.com 10.1186/1471-2105-8-4
66. Vivona S., et al. NERVE: new enhanced reverse vaccinology environment. BMC Biotechnol. 6 (2006) 35. http://www.biomedcentral.com 10.1186/1472-6750-6-35
67. Saha S., and Raghava G.P. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 34 (2006) W202-W209
68. Fiers M.W., et al. Allermatch, a webtool for the prediction of potential allergenicity according to current FAO/WHO Codex alimentarius guidelines. BMC Bioinformatics 5 (2004) 133. http://www.biomedcentral.com 10.1186/1471-2105-5-133